Literature DB >> 7256088

Host defense against Streptococcus pneumoniae: the role of the spleen.

D W Wara.   

Abstract

The asplenic patient has an increased susceptibility to bacterial septicemia. Streptococcus pneumoniae is responsible for approximately 50% of the episodes. Although the incidence of septicemia varies among patients of different ages and with different underlying diseases, half of the patients with overwhelming post-splenectomy infection die. Increased susceptibility to overwhelming infection with blood-borne bacteria is due primarily to the absence of a major phagocytic mass with a large blood flow. In the nonimmune host the spleen plays an important role in the phagocytosis and clearance of blood-borne antigens. Asplenic infants younger than two years old or splenectomized patients with an underlying disease that impairs their ability to form specific antibody to S. pneumoniae are at maximal risk for septicemia. In addition, studies of asplenic animals and humans suggest that the spleen has a specific role in the production of antibody. Activation of the alternative complement pathway may be abnormal in patients with anatomical or functional asplenia. Defective clearance of blood-borne bacteria in the nonimmune host, a decrease in antibody formation, and abnormal activation of the alternative complement pathway may be additive defects that place the asplenic host at risk for overwhelming post-splenectomy infection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7256088     DOI: 10.1093/clinids/3.2.299

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  15 in total

1.  Elevated natural killer (NK) cytotoxicity of mononuclear leucocytes from splenectomized patients: increase in Leu-7+ and Leu-11+ leucocytes.

Authors:  A Ferrante; G K Kiroff; P A Drew
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

2.  Partial splenectomy in children: an alternative for splenectomy in the pathological staging of Hodgkin's disease.

Authors:  H J Hoekstra; R Y Tamminga; W Timens
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

3.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

4.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

5.  Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway.

Authors:  T Magnus; B M Andersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

6.  Splenic autotransplantation and the immune system. Adequate testing required for evaluation of effect.

Authors:  W Timens; R Leemans
Journal:  Ann Surg       Date:  1992-03       Impact factor: 12.969

7.  Antibody responses to capsular polysaccharide, lipopolysaccharide, and outer membrane in adults infected with Haemophilus influenzae type b.

Authors:  T Lagergård; O Nylén; T Sandberg; B Trollfors
Journal:  J Clin Microbiol       Date:  1984-12       Impact factor: 5.948

8.  Pneumococcal bacteremia in cancer patients.

Authors:  V Richard; F Meunier; P Van der Auwera; P Dejace; D Daneau; J Klastersky
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082

9.  Effects of cytokines, complement, and antibody on the neutrophil respiratory burst and phagocytic response to Plasmodium falciparum merozoites.

Authors:  L M Kumaratilake; A Ferrante; T Jaeger; C M Rzepczyk
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

10.  Prophylactic effect of human immunoglobulin against pneumococcal post-splenectomy sepsis in the rat.

Authors:  K Offenbartl; P Christensen; P Gullstrand; K Prellner
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.